Baricitinib in the Treatment of Intestinal Behçet's Syndrome

NCT06849908 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Behcet Syndrome, Intestinal Type

Interventions

DRUG: Baricitinib
DRUG: Adalimumab

Sponsor

Peking Union Medical College Hospital